Obesity jabs could cut the risk of heart attacks and strokes in people even if they fail to lose much weight, according to an ...
Those taking the drugs for at least three years cut their risk of heart attack, stroke or cardiac death by 20 per cent ...
The drug Wegovy uses an active ingredient called Semaglutide which is part of a growing class of GLP-1 drugs that make people ...
Marketed as Wegovy, Ozempic and Rybelsus, semaglutide injections may benefit obese patients even if they don't lose weight.
Weight loss jabs like Ozempic cuts risk of heart attack and stroke, study claims - Risk of serious conditions reduced ...
Patients taking semaglutide had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease after three ...
Ozempic could dramatically reduce the risk of heart attacks and stroke, a new study indicates. The weight loss jab has become ...
A study has found the anti-obesity drug sold under brand names Wegovy, Ozempic and Rybelsus could reduce the risk of heart attacks, strokes ...
A weight loss injection could reduce the risk of heart attacks and benefit the cardiovascular health of adults, according to a study on what could be the largest medical breakthrough since statins.
As a major study shows it cuts heart attack risks experts say semaglutide could 'transform many chronic diseases of ageing' ...